RxDoctor Payments Data

Joby Jacob, MD

Internal Medicine · Levittown, PANPI 1477043248

Payments from drug & device makers

$744in general payments, 2019–2025

Across 33 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$117
  • Otsuka America Pharmaceutical, Inc.$100
  • Alpha Cognition USA, Inc.$84
  • AbbVie$65
  • Lundbeck LLC$60
  • Johnson & Johnson$58
  • plus $260 from 10 others

What the payments were for

  • Food & beverage$67390%
  • Education$7110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$744 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$542,190
Medicare patients
814
Services billed
4,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban558$154,626
Austedo XrDeutetrabenazine15$54,179
BiktarvyBictegrav/Emtricit/Tenofov Ala12$50,498
RexultiBrexpiprazole39$32,117
XareltoRivaroxaban120$30,583
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$24,170
FarxigaDapagliflozin Propanediol47$17,570
MyrbetriqMirabegron82$17,414
Dalfampridine ErDalfampridine14$14,907
Atorvastatin Calcium1,268$14,813
OzempicSemaglutide14$14,399
JanuviaSitagliptin Phosphate54$13,471
EntrestoSacubitril/Valsartan42$11,211
Memantine Hcl166$9,519
Darunavir12$8,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$154,626558 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$117$54,17915 claims
Otsuka America Pharmaceutical, Inc.Rexulti$100$32,11739 claims
Johnson & JohnsonXarelto$58$30,583120 claims
GSKTrelegy Ellipta, Incruse Ellipta$15$28,49344 claims
Boehringer IngelheimSpiriva Respimat, Tradjenta, Jardiance$24$18,54347 claims
AbbVieNamzaric$65$7,19312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Levittown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →